Skip to content
Clinical Trials – home

Hippokration Hospital

Verified siteinfo

Greece Vassilissas Sofias Avenue 114, 115 27 Athens, Greece

  • 34 trials recruiting
  • Arteriosclerosis · Hypertension · Chronic kidney disease
  • Adults and children

About Specializations

Hippokration Hospital in Athens, Greece specialises in clinical trials of conditions such as Arteriosclerosis, Hypertension, Chronic kidney disease, Metabolic dysfunction-associated steatohepatitis, and other specialisations. This site conducts important research.

Main research areas of the site

Gastroenterology

The medical center is at the forefront of gastroenterology research, focusing on innovative treatments for conditions such as ulcerative colitis. Through clinical trials, the center evaluates the efficacy of novel therapies aimed at inducing remission and maintaining long-term health in pediatric and adult patients.

  • Ulcerative Colitis
  • Primary Biliary Cholangitis
  • Erosive Esophagitis

By advancing therapeutic options, the center contributes significantly to improving the quality of life for patients with chronic gastrointestinal disorders.

Rheumatology and Autoimmune Diseases

Specializing in rheumatology and autoimmune diseases, the center conducts extensive research on systemic lupus erythematosus (SLE) and Sjögren’s syndrome. The focus is on developing treatments that reduce disease activity and improve patient outcomes.

  • Systemic Lupus Erythematosus (SLE)
  • Sjögren’s Syndrome
  • Giant Cell Arteritis

Through these efforts, the center is paving the way for more effective management of complex autoimmune conditions.

Cardiology

The center is a leader in cardiology research, particularly in the treatment of heart failure and hypertrophic cardiomyopathy. By exploring new pharmacological interventions, the center aims to reduce cardiovascular events and improve heart function.

  • Heart Failure
  • Hypertrophic Cardiomyopathy
  • Arterial Hypertension

These advancements are crucial in addressing the growing burden of heart diseases worldwide.

Nephrology

In the field of nephrology, the center is dedicated to improving outcomes for patients with chronic kidney disease and related conditions. Research efforts focus on innovative therapies that slow disease progression and enhance renal function.

  • Chronic Kidney Disease
  • IgA Nephropathy
  • Focal Segmental Glomerulosclerosis

These studies are instrumental in developing new standards of care for kidney health.

Hematology

The center's hematology research is focused on advancing treatments for blood disorders such as sickle cell disease and thalassemia. By investigating novel therapeutic agents, the center aims to improve patient survival and quality of life.

  • Sickle Cell Disease
  • Thalassemia
  • Hemophilia A

These efforts are crucial in providing new hope for patients with hereditary blood disorders.

Endocrinology and Metabolic Disorders

In endocrinology, the center is pioneering research on metabolic disorders, including diabetes and Cushing's syndrome. The focus is on developing therapies that manage symptoms and prevent complications.

  • Diabetes Mellitus
  • Cushing's Syndrome
  • Non-alcoholic Steatohepatitis (NASH)

These studies are vital in addressing the global challenge of metabolic health.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Site location
Vassilissas Sofias Avenue 114115 27 AthensGreece
Recruiting now
34 trials
Conditions studied
63
Partner status
Verified site

More sites in AthensGreece

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

90 clinical trials

Cardiac failure

Recruiting

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational
Countries:GreeceGreece
  • Participants:18–64 years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Long‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:SPY001-001
  • Sponsor:Spyre Therapeutics Inc.

A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

A Study of Long-acting Antibodies SPY001-001 and SPY002 Alone and Combined for Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:SPY001-001
  • Sponsor:Spyre Therapeutics Inc.

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Zilebesiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Crohn's disease

Recruiting

Study of icotrokinra for adults with moderately to severely active Crohn's disease

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Icotrokinra
  • Sponsor:Janssen Cilag International

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Laroprovstat
  • Sponsor:AstraZeneca AB

Study on the Effects of Baxdrostat and Dapagliflozin in Adults with Chronic Kidney Disease and High Blood Pressure

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Study on Eltrekibart and Mirikizumab for Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Mirikizumab
  • Sponsor:Eli Lilly & Co.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.